{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.16","value":"-23.16"},{"groupId":"OG001","spread":"22.92","value":"-25.31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30) Global Health Status score measures a cancer patient's perception of their overall health and well-being and ranges from 0 (worst) to 100 (best). A positive change from baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin\n\nCisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG000","title":"IMRT + Cisplatin"},{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab\n\nCetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG001","title":"IMRT + Cetuximab"}],"paramType":"MEAN","populationDescription":"Eligible participants enrolled to the quality of life (QOL) substudy who received protocol treatment and had outcome measure data.","reportingStatus":"POSTED","timeFrame":"Baseline and end of treatment (6-7 weeks)","title":"EORTC QLQ-C30 Global Health Status Score Change From Baseline at End of Treatment","type":"SECONDARY","unitOfMeasure":"score on a scale"}